Demographic characteristics of study patients and the propensity score-matched sample by medicine use
| Beta-blocker or combination drug use | ||||
| No (n=6168) | Yes (n=6168) | |||
| n | % | n | % | |
| Age, median (IQR) | 60.6 (47.7–71.4) | 60.5 (47.7–70.4) | ||
| Stratify age | ||||
| 20–49 | 1772 | 28.7 | 1812 | 29.4 |
| 50–64 | 1928 | 31.3 | 1949 | 31.6 |
| 65+ | 2468 | 40 | 2407 | 39 |
| Gender | ||||
| Women | 3112 | 50.5 | 3135 | 50.8 |
| Men | 3056 | 49.6 | 3033 | 49.2 |
| Comorbidity | ||||
| Hypertension | 3240 | 52.5 | 3058 | 49.6 |
| Hyperlipidaemia | 2313 | 37.5 | 2207 | 35.8 |
| Diabetes mellitus | 1452 | 23.5 | 1363 | 22.1 |
| COPD | 1038 | 16.8 | 1013 | 16.4 |
| Asthma | 588 | 9.53 | 561 | 9.1 |
| CKD | 535 | 8.67 | 493 | 7.99 |
| History of pneumonia | 206 | 3.34 | 204 | 3.31 |
| History of acute respiratory failure | 38 | 0.62 | 41 | 0.66 |
| History of coronary artery disease | 1642 | 26.6 | 1588 | 25.8 |
| History of stroke | 474 | 7.68 | 426 | 6.91 |
| Other glaucoma medications | ||||
| PGA | 421 | 6.83 | 504 | 8.17 |
| CAI | 366 | 5.93 | 412 | 6.68 |
| Alpha agonist | 575 | 9.32 | 593 | 9.61 |
| Pilocarpine | 909 | 14.7 | 818 | 13.3 |
CAI, carbonic anhydrase inhibitor; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PGA, prostaglandin analogue.